Scarica l'app Stockscreener
45.30
1.99%
-0.895
Precedente Chiudi:
$46.20
Aprire:
$45.83
Volume 24 ore:
109.07K
Relative Volume:
0.28
Capitalizzazione di mercato:
$2.18B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+11.06%
1M Prestazione:
+7.04%
6M Prestazione:
+156.69%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$45.10
$47.36
Intervallo di 1 settimana:
$38.62
$47.36
Portata 52W:
$6.71
$47.36
Maze Therapeutics Inc Stock (MAZE) Company Profile
Nome
Maze Therapeutics Inc
Settore
Industria
Telefono
(650) 850-5070
Indirizzo
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Confronta MAZE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
45.30 | 2.22B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.89 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.65 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.59 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.52 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-04 | Iniziato | Wells Fargo | Overweight |
| 2025-11-14 | Iniziato | Raymond James | Outperform |
| 2025-09-02 | Iniziato | BTIG Research | Buy |
| 2025-07-23 | Iniziato | H.C. Wainwright | Buy |
| 2025-07-08 | Iniziato | Wedbush | Outperform |
Maze Therapeutics Inc Borsa (MAZE) Ultime notizie
Retail Surge: What’s the fair value of Maze Therapeutics Inc. stockQuarterly Portfolio Summary & High Accuracy Investment Entry Signals - mfd.ru
First Week of March 20th Options Trading For Maze Therapeutics (MAZE) - Nasdaq
Maze Therapeutics (NASDAQ:MAZE) Reaches New 1-Year HighWhat's Next? - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Price Target Raised to $46.00 - Defense World
Maze Therapeutics (NASDAQ:MAZE) Cut to "Sell" at Wall Street Zen - MarketBeat
BTIG Research Raises Maze Therapeutics (NASDAQ:MAZE) Price Target to $46.00 - MarketBeat
Maze Therapeutics: An Innovative, Nature-Driven Platform (NASDAQ:MAZE) - Seeking Alpha
Assessing Maze Therapeutics (MAZE) Valuation After Its Recent Share Price Momentum - Sahm
What dividend safety score for Maze Therapeutics Inc. stockInflation Watch & Proven Capital Preservation Tips - Bộ Nội Vụ
Gainers Report: How Maze Therapeutics Inc stock valuations compare to rivals2025 Technical Patterns & AI Forecast for Swing Trade Picks - Bộ Nội Vụ
How Maze Therapeutics Inc. stock benefits from tech adoptionJuly 2025 Final Week & Risk Managed Investment Entry Signals - Улправда
How Maze Therapeutics Inc. stock valuations compare to rivalsStock Surge & Low Risk Profit Maximizing Plans - Улправда
Maze Therapeutics (NASDAQ:MAZE) CMO Sells 25,156 Shares - MarketBeat
Maze Therapeutics (MAZE) Stock Analysis: Exploring a 21.52% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Maze Therapeutics Director Makes Major Insider Move With High-Value Stock Sale - TipRanks
How rising interest rates impact Maze Therapeutics Inc. stock2025 Sector Review & Daily Momentum Trading Reports - Улправда
How Maze Therapeutics Inc. stock reacts to oil pricesJuly 2025 Technicals & Daily Oversold Stock Bounce Ideas - Улправда
Is Maze Therapeutics Inc. stock trading at a premium valuation2025 Bull vs Bear & Safe Capital Growth Stock Tips - Улправда
What sentiment indicators say about Maze Therapeutics Inc. stockQuarterly Profit Summary & Reliable Price Breakout Alerts - Улправда
Is Maze Therapeutics Inc. stock supported by innovation pipeline2025 Technical Patterns & Expert Approved Trade Ideas - Улправда
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells 412 Shares of Stock - MarketBeat
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
BERNSTEIN HAROLD Insider Trades - Nasdaq
Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 4.9% – Here’s Why - Defense World
Aug Patterns: How Maze Therapeutics Inc stock compares to market leadersWeekly Trade Summary & Free High Accuracy Swing Entry Alerts - moha.gov.vn
Maze Therapeutics (NASDAQ:MAZE) Trading Down 4.9%Here's Why - MarketBeat
Amy Bachrodt Sells 5,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - Defense World
Amy Bachrodt Sells 10,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - Defense World
Harold Bernstein Sells 45,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - Defense World
Atul Dandekar Sells 72,400 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - Defense World
Maze Therapeutics SVP, finance sells $606k in shares By Investing.com - Investing.com Australia
Maze Therapeutics (NASDAQ:MAZE) CMO Sells $1,825,200.00 in Stock - MarketBeat
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) SVP Sells 5,000 Shares of Stock - MarketBeat
Maze Therapeutics SVP, finance sells $606k in shares - Investing.com
Maze Therapeutics Insider Sold Shares Worth $1,825,355, According to a Recent SEC Filing - marketscreener.com
Maze Therapeutics Executives Engage in Significant Stock Transactions - TradingView — Track All Markets
Maze Therapeutics (NASDAQ:MAZE) Insider Sells $2,936,544.00 in Stock - MarketBeat
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Growth Recap: Is Maze Therapeutics Inc stock trading at a premium valuationEarnings Overview Summary & Free Real-Time Volume Trigger Notifications - Bộ Nội Vụ
New way to pay for at‑home AI neurorehab aims to widen access - Stock Titan
We Think Maze Therapeutics (NASDAQ:MAZE) Can Easily Afford To Drive Business Growth - Yahoo Finance
FY2025 Earnings Estimate for MAZE Issued By Lifesci Capital - MarketBeat
Maze Therapeutics price target raised to $46 from $34 at Guggenheim - MSN
Maze Therapeutics (NASDAQ:MAZE) Stock Rating Upgraded by Lifesci Capital - Defense World
Guggenheim raises Maze Therapeutics stock price target to $46 on CKD program - Investing.com Canada
Lifesci Capital Upgrades Maze Therapeutics (NASDAQ:MAZE) to Strong-Buy - MarketBeat
Leerink Partners raises Maze Therapeutics stock price target to $50 on AMKD study - Investing.com Canada
Edison Issues Report on MindMaze Therapeutics (MMTX) - TMX Newsfile
MindMaze Therapeutics (SIX: MMTX) issues 140M shares to acquire NeuroX - Stock Titan
Maze Therapeutics Inc Azioni (MAZE) Dati Finanziari
Non sono disponibili dati finanziari per Maze Therapeutics Inc (MAZE). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
4.38%
1.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):